You are here: Welcome to the MPKB » Welcome to the MPKB » Publications & presentations » Poster - Molecular static and dynamic analyses reveal flaw in murine model used by US FDA to detect drug carcinogenicity
Home

Differences

This shows you the differences between two versions of the page.

Link to this comparison view

Both sides previous revisionPrevious revision
home:publications:marshall_days_of_molecular_medicine_2007 [09.05.2010] – paulalberthome:publications:marshall_days_of_molecular_medicine_2007 [09.14.2022] (current) – external edit 127.0.0.1
Line 6: Line 6:
 **Type:** Abstract presentation\\ **Type:** Abstract presentation\\
 **Presented by:**  Trevor Marshall, PhD\\ **Presented by:**  Trevor Marshall, PhD\\
-**Conference:**  [[http://www.nature.com/nm/meetings/dmm2007/program.html|Days of Molecular Medicine 2007]]\\+**Conference:**  [[https://www.nature.com/nm/meetings/dmm2007/program.html|Days of Molecular Medicine 2007]]\\
 **Location:**  Harvard University\\ **Location:**  Harvard University\\
 **Date:**  2007\\ **Date:**  2007\\
-**Additional content:** [[http://autoimmunityresearch.org/transcripts/dmm2007-harvard.pdf|poster]]; [[http://autoimmunityresearch.org/dmm2007/dmm2007.ram|video showing difference in steady-state ligand conformation between rat and human VDR]]+**Additional content:** [[https://autoimmunityresearch.org/transcripts/dmm2007-harvard.pdf|poster]]; [[https://autoimmunityresearch.org/dmm2007/dmm2007.ram|video showing difference in steady-state ligand conformation between rat and human VDR]]
  
  
Line 22: Line 22:
 exhaustive. For example, during the acceptance testing of the ARB exhaustive. For example, during the acceptance testing of the ARB
 Olmesartan((FDA CDER: NDA-21-286, Sankyo Pharma Inc Available from URL Olmesartan((FDA CDER: NDA-21-286, Sankyo Pharma Inc Available from URL
-http://www.fda.gov/cder/foi/nda/2002/21-286_Benicar.htm)), possible carcinogenicity observed in hamsters was not+https://www.fda.gov/cder/foi/nda/2002/21-286_Benicar.htm)), possible carcinogenicity observed in hamsters was not
 able to be duplicated in rats, or in transgenic mice. We have previously able to be duplicated in rats, or in transgenic mice. We have previously
 used the static molecular modeling of AutoDock to demonstrate that used the static molecular modeling of AutoDock to demonstrate that
Line 34: Line 34:
 Olmesartan was the ligand, while the human VDR was activated by Olmesartan was the ligand, while the human VDR was activated by
 Olmesartan similarly to its native ligand (1,25-dihydroxyvitamin-D). Olmesartan similarly to its native ligand (1,25-dihydroxyvitamin-D).
-Since the VDR is believed to express 913 genes(({{pubmed>long:16002434}}))+Since the VDR is believed to express 913 genes(({{pmid>long:16002434}}))
 This video was created using the GROMACS Molecular This video was created using the GROMACS Molecular
 Dynamics software on a small computing cluster assembled Dynamics software on a small computing cluster assembled
Line 40: Line 40:
 difference in steady-state ligand conformation between difference in steady-state ligand conformation between
 human and rat VDR can clearly be seen at human and rat VDR can clearly be seen at
-http://autoimmunityresearch.org/dmm2007/dmm2007.ram, many of which are+https://autoimmunityresearch.org/dmm2007/dmm2007.ram, many of which are
 known to be associated with cancer pathogenesis, good homology known to be associated with cancer pathogenesis, good homology
 between human VDR, and the animal model VDR, is exceedingly between human VDR, and the animal model VDR, is exceedingly
home/publications/marshall_days_of_molecular_medicine_2007.1283693054.txt.gz · Last modified: 09.05.2010 by paulalbert
© 2015, Autoimmunity Research Foundation. All Rights Reserved.